expand

The Feinstein Institute for Medical Research

Empowering Imagination. Pioneering Discovery.
Print | Font Size ( + ) ( - ) | Bookmark | Email

Christoph U. Correll, MD

Medical Director, Recognition and Prevention Program (RAP) The Zucker Hillside Hospital

Professor, Psychiatry and Molecular Medicine, Hofstra North Shore-LIJ School of Medicine

Investigator, The Feinstein Institute for Medical Research

Phone: (718) 470-4812
Email: ccorrell@lij.edu

About the Investigator
Christoph Correll, MD, is currently professor of psychiatry and molecular medicine at Hofstra North Shore-LIJ School of Medicine and medical director of the Recognition and Prevention (RAP) program at the Zucker Hillside Hospital in New York. He completed his medical studies at the Free University of Berlin in Germany and Dundee University Medical School in Scotland. After finishing his general psychiatry residency at the Zucker Hillside Hospital in Glen Oaks, New York, he trained in child and adolescent psychiatry at Schneider Children’s Hospital in New Hyde Park, New York.

Dr. Correll’s research and clinical work focus on the identification, characterization, and treatment of adults and youths with severe psychiatric disorders. His areas of expertise include the prodrome, first episode, multi-episode, and refractory illness phase of severe psychotic and mood disorders, including schizophrenia, bipolar disorder, and major depression, as well as aggressive spectrum disorders. He further focuses on psychopharmacology and comparative effectiveness, the risk–benefit evaluation of psychotropic medications, as well as the extent and mechanisms of cardiometabolic and neuromotor adverse effects.

Dr. Correll has authored or co-authored more than 350 journal articles and has served on several expert consensus panels on the use of antipsychotics across a range of psychiatric disorders. He is a reviewer for more than 70 peer-reviewed journals and an editorial board member of 11 scientific journals. Dr. Correll is the principal investigator or Steering Committee member of several large, federally funded grants. He has received more than 30 national and international research awards and fellowships for his work, and he was listed in 2014 by Thompson Reuters as one of “the most influential scientific minds” and top 1% cited scientists in the area of psychiatry.

Research Focus

Dr. Correll’s research and clinical work focus on the identification, characterization and psychopharmacological management of adults and youth with severe psychiatric disorders. His areas of expertise include schizophrenia, bipolar disorder, major depression and other psychotic, mood and autism/disruptive behavior spectrum disorders, ranging from the prodrome to first episode, multi-episode and refractory illness patients. His work focuses further on the risk-benefit evaluation of psychotropic medications, including the interface between psychiatry and medicine and investigations of the extent and mechanisms of neuromotor and cardiometabolic adverse effects.

Dr. Correll and his team are conducting several studies on beneficial effects and side effects of antipsychotics and mood stabilizers; symptomatic, diagnostic and functional outcomes of youth with psychiatric problems and on clinical and biological risk factors and protective factors predicting outcomes. These research projects involve naturalistic and randomized treatment, controlled and observational studies.

SATIETY study (sponsor: National Institute of Mental Health): children and adolescents (age 4-19 years) who start clinically decided antipsychotic treatment are followed in an observational cohort study design to assess the risks and benefits of these medications under real world conditions. Effectiveness, adverse effects and clinical and biological predictors of these effects are studied.

IMPACT study (sponsor: National Institute of Mental Health): children and adolescents (age 8-19 years) who have gained significant amount of their body weight over the past 3 years on an antipsychotic and who are overweight are randomized to up to 6 months of open treatment of a) healthy lifestyle instruction alone or b) addition of metformin or c) a switch to a lower risk antipsychotic.

STRATEGY study: children and adolescents (age 10-19 years) who are either starting antipsychotic treatment for the first time ever, or who have gained at least 10% of their body weight over the past 12 months while treated with an antipsychotic are randomized to 3 months of open treatment of a) healthy lifestyle instruction alone or b) addition of metformin.

Adolescent Mood Disorder and Psychosis Study: children and adolescents (age 12-18 years) who have a clinical diagnosis of a mood or psychosis spectrum disorder are interviewed to comprehensively characterize their psychiatric problems and followed in an observational cohort design to assess symptomatic and functional outcomes over time.

Dr. Correll has authored or co-authored over 200 journal articles. He has served on several expert consensus panels on the use of antipsychotics across a range of psychiatric disorders, is a reviewer for over 70 peer-reviewed journals and an editorial board member of ten scientific journals. Dr. Correll is the principal investigator or Steering Committee member of several large, federally funded grants and has received over two dozen national and international research awards and fellowships for his work.

Education

Free University of Berlin, Berlin, Germany
Degree: MD
1993
Field of Study: Pre-Medicine & Medicine

Dundee University, Dundee, Great Britain
Degree: MD
1991
Field of Study: Medicine

Neurologische Klinik GmbH, Bad Neustadt, Germany
Degree: Resident
1997
Field of Study: Neurology Residency

PGY-1, Beth Israel Medical Center, New York, NY
Degree: Resident
1998
Field of Study: Psychiatry Residency

Hillside Hospital, Glen Oaks, NY
2001
Field of Study: Psychiatry Research Residency (Chief)

Schneider Children’s Hospital, New Hyde Park, NY
2003
Field of Study: Child & Adolescent Psychiatry Fellow

Awards & Honors

2002 11th Biennial Winter Workshop on Schizophrenia Young Scientist Award; Peter Henderson, M.D., Memorial Paper Award; Clinical Research Methodology Workshop American Society of Clinical Psychopharmacology Fellowship Award; APA/Lilly Resident Research Award; Seventh APA Research Colloquium for Junior Investigators Award; ACAP Presidential Scholar Award

2003 AADPRT George Ginsberg Fellowship Award; American Federation for Medical Research Clinical Research 2003 Conference Travel Award; American Federation for Medical Research Henry Christian Award; APA Research Colloquium for Junior Investigators Award; Clinical Research Methodology Workshop American Society of Clinical Psychopharmacology Fellowship Award; John and Maxine Bendheim Fellowship Award for Research

2004 APA Research Colloquium for Junior Investigators Award; AACAP Pilot Research Award; North Shore – Long Island Jewish Research Institute Faculty Research Award

2005 International Congress on Schizophrenia Research Young Investigator Award; First NIMH-sponsored Career Development Institute for BPD Fellowship Award; First Neuroleptic Malignant Syndrome Information Service 2004-2005 Promising New Investigators Award

2007 NARSAD Young Investigator Award

2013 John and Maxine Bendheim Fellowship Award for Research

Publications
  1. Cornblatt BA, Carrión RE, Auther A, McLaughlin D, Olsen RH, John M, Correll CU. “Psychosis Prevention: A Modified Clinical High Risk Perspective From the Recognition and Prevention (RAP) Program.” Am J Psychiatry. 2015 Jun 5. [Epub ahead of print]
  2. Correll CU, Skuban A, Ouyang J, Hobart M, Pfister S, McQuade RD, Nyilas M, Carson WH, Sanchez R, Eriksson H. “Efficacy and Safety of Brexpiprazole for the Treatment of Acute Schizophrenia: A 6-Week Randomized, Double-Blind, Placebo-Controlled Trial.” Am J Psychiatry. 2015 Apr 16 [Epub ahead of print]
  3. Correll CU, Joffe BI, Rosen LM, Sullivan TB, Joffe RT. “Cardiovascular and cerebrovascular risk factors and events associated with second-generation antipsychotic compared to antidepressant use in a non-elderly adult sample: results from a claims-based inception cohort study.” World Psychiatry. 2015 Feb;14(1):56-63.
  4. Correll CU, Robinson DG, Schooler NR, Brunette MF, Mueser KT, Rosenheck RA, Marcy P, Addington J, Estroff SE, Robinson J, Penn D, Azrin S, Goldstein A, Severe J, Heinssen R, Kane JM. “Cardiometabolic Risk in First Episode Schizophrenia-Spectrum Disorder Patients: Baseline Results from the RAISE-ETP Study.” JAMA Psychiatry 2014 Dec 1;71(12):1350-63.
  5. Correll CU, Olvet D, Auther A, Hauser M, Kishimoto T, Synder S, Carrión RE, Cornblatt BA. “The Bipolar Prodrome Symptom Interview and Scale-Prospective (BPSS-P): Description and Validation in a Clinical High Risk Psychiatric Sample and Healthy Controls.” Bipolar Disord. Aug;16(5):505-22.
  6. Correll CU, Detraux J, De Lepeleire J, De Hert M. “Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder.” World Psychiatry. 2015 Jun;14(2):119-136.
  7. Olfson M, Blanco C, Wang S, Laje G, Correll CU.  “National Trends in the Mental Health Care of Children and Adolescents by Office-Based Physicians.” JAMA Psychiatry. 2014 Jan 1;71(1):81-90.
  8. Kishimoto T, Agarwal V, Kishi T, Leucht S, Kane JM, Correll CU. “Maintenance Treatment and Relapse Prevention in Schizophrenia: Systematic Review and Meta-analysis of Randomized Controlled Trials of First-Generation and Second-Generation Antipsychotics.” Mol Psychiatry. 2013 Jan;18(1):53-66.
  9. De Hert M, Detraux J, van Winkel R, Yu W, Correll CU. “Metabolic and cardiovascular adverse effects associated with antipsychotic drugs.” Nat Rev Endocrinol. 2011 Oct 18;8(2):114-26.
  10. Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane JM, Malhotra AK. “Cardiometabolic risk of atypical antipsychotics during first-time use in children and adolescents.” JAMA 2009, Oct 28;302(16): 1763-1771.

View more at PubMed